Suicidal Ideation in Major Depressive Disorder | Treatment Algorithms | Claims Data Analysis | US | 2018
A subset of major depressive disorder (MDD) patients experience suicidal ideation (SID). Because of the potential lethality of SID, SID in MDD is a highly drug-treated condition that uses an array of drug classes including, but not limited to, selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, and—as adjunctive therapies—atypical antipsychotics. Such therapies are intended to treat MDD and, by extension, address SID. Even though the drug market is entrenched with generic therapies, MDD patients’ heterogeneous responses to a treatment give branded drugs (e.g., Trintellix [Lundbeck/Takeda], Rexulti [Otsuka/Lundbeck]) the opportunity for use, often as later-line therapies. Given MDD’s crowded and competitive landscape, drug marketers and developers will find value in understanding how MDD patients with SID are being treated based on real-world data.
Questions Answered
- What patient share do key therapies and brands garner by line of therapy in MDD patients newly diagnosed with SID? What are the quarterly trends in prescribing among recently treated and newly diagnosed MDD patients with SID?
- How has Trintellix been integrated into the treatment algorithm?
- What proportion of MDD patients with SID receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of MDD patients with SID are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated MDD patients with SID?
Product Description
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Otsuka, Lundbeck, Takeda, Allergan
Key drugs: Aripiprazole (Abilify, generics), citalopram, trazodone, Fetzima, Rexulti, Trintellix, Viibryd
Key analysis provided:
- Brand Usage Across Longitudinal Patient Sample.
- Newly Diagnosed Patient Analysis.
- Treatment Initiation and Progression.
- Line of Therapy Analysis.
- Combination Therapy Analysis.
- Source of Business for Recently Treated Patients.
- Persistency and Compliance Analysis.
- Product-Level Patient Flow Charts.
